

Roche - AVAglio Study Positive: PFS Endpoint Met in Glioblastoma

<https://marketpublishers.com/r/R8F6F717F56EN.html>

Date: August 2012

Pages: 2

Price: US\$ 90.00 (Single User License)

ID: R8F6F717F56EN

Abstracts

Roche reported that Avastin plus radiation and temozolomide chemotherapy significantly improved progression free survival as first-line therapy in glioblastoma. We expect a successful approval and the indication should add \$750m in sales for Avastin. The final overall survival data is expected in 2013. In the Phase 2 trial Avastin in combination with standard of care has demonstrated an OS of 19.6 m in the first line setting, while the standard of Care –Temodar with radiotherapy was associated with an OS of 14.6 m in the first line setting. On the basis of PhII data, Avastin was granted accelerated approval as monotherapy in recurrent Glioblastoma in the US in 2009.

I would like to order

Product name: Roche - AVAglio Study Positive: PFS Endpoint Met in Glioblastoma

Product link: <https://marketpublishers.com/r/R8F6F717F56EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R8F6F717F56EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970